LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.21

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.2

Max

1.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
EPS	-0.43
Gewinnspanne	-2,190.837
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+147.93% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-26M 76M
Vorheriger Eröffnungskurs	1.21
Vorheriger Schlusskurs	1.21

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Dez. 2025, 17:29 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. Dez. 2025, 16:47 UTC

Wichtige Markttreiber

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. Dez. 2025, 16:10 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20. Dez. 2025, 19:00 UTC

Ergebnisse

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19. Dez. 2025, 22:33 UTC

Ergebnisse

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. Dez. 2025, 22:19 UTC

Ergebnisse

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. Dez. 2025, 21:48 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 21:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. Dez. 2025, 21:38 UTC

Ergebnisse

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. Dez. 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. Dez. 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. Dez. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. Dez. 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. Dez. 2025, 18:00 UTC

Market Talk

Ergebnisse

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. Dez. 2025, 17:41 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. Dez. 2025, 17:24 UTC

Market Talk

Ergebnisse

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. Dez. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

19. Dez. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. Dez. 2025, 16:29 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. Dez. 2025, 16:20 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. Dez. 2025, 16:19 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. Dez. 2025, 16:18 UTC

Akquisitionen, Fusionen, Übernahmen

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. Dez. 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Dez. 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. Dez. 2025, 16:05 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 16:04 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. Dez. 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. Dez. 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. Dez. 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. Dez. 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

147.93% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 147.93%

Hoch 4 USD

Tief 2 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.